The strategic activation of the AHR through a selective AHR modulator (SAhRM) may offer effective anti-tumour therapy in VHL-mutated ccRCC, reducing the need for surgical interventions [71,73]. Here, VHL is linked to nonpapillary renal cell carcinoma.